| Literature DB >> 33806155 |
Ieva Bagdonaite1, Andrew J Thompson2, Xiaoning Wang2, Max Søgaard3, Cyrielle Fougeroux4,5, Martin Frank6, Jolene K Diedrich2, John R Yates2, Ali Salanti4, Sergey Y Vakhrushev1, James C Paulson2, Hans H Wandall1.
Abstract
Enveloped viruses hijack not only the host translation processes, but also its glycosylation machinery, and to a variable extent cover viral surface proteins with tolerogenic host-like structures. SARS-CoV-2 surface protein S presents as a trimer on the viral surface and is covered by a dense shield of N-linked glycans, and a few O-glycosites have been reported. The location of O-glycans is controlled by a large family of initiating enzymes with variable expression in cells and tissues and hence is difficult to predict. Here, we used our well-established O-glycoproteomic workflows to map the precise positions of O-linked glycosylation sites on three different entities of protein S-insect cell or human cell-produced ectodomains, or insect cell derived receptor binding domain (RBD). In total 25 O-glycosites were identified, with similar patterns in the two ectodomains of different cell origin, and a distinct pattern of the monomeric RBD. Strikingly, 16 out of 25 O-glycosites were located within three amino acids from known N-glycosites. However, O-glycosylation was primarily found on peptides that were unoccupied by N-glycans, and otherwise had low overall occupancy. This suggests possible complementary functions of O-glycans in immune shielding and negligible effects of O-glycosylation on subunit vaccine design for SARS-CoV-2.Entities:
Keywords: COVID-19; GalNAc; O-glycoproteomics; O-glycosylation; SARS-CoV-2; molecular modelling; site-specific glycosylation
Year: 2021 PMID: 33806155 DOI: 10.3390/v13040551
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048